NeurAxis Announces Blue Cross and Blue Shield of Kansas City Policy Coverage
- None.
- None.
Insights
The announcement by NeurAxis, Inc. of securing policy coverage from Blue Cross and Blue Shield of Kansas City (BCBSKC) marks a significant milestone for the company. The expansion to cover approximately one million additional lives under BCBSKC is a strategic move that could potentially increase the company's revenue streams. Insurer acceptance is often a critical driver for medical technology firms as it directly influences the adoption rate of their technologies.
From a financial perspective, this development could lead to an uptick in the company's stock as investors often react positively to expanded market access. The increased coverage also indicates confidence in NeurAxis's neuromodulation therapies, which could lead to further insurer partnerships and enhance the company's bargaining power in price negotiations.
Long-term, the company's focus on leveraging clinical evidence to obtain payer coverage is a sustainable strategy that could solidify its position in the market. However, investors should monitor the actual market adoption rates and the company's ability to capitalize on this expanded coverage to gauge the real financial impact.
The endorsement by a significant insurer such as BCBSKC for NeurAxis's neuromodulation therapy, IB-Stim, is a testament to the therapy's clinical evidence. Coverage by insurers is contingent on the demonstration of both efficacy and cost-effectiveness of medical technologies. This coverage indicates that NeurAxis's IB-Stim has likely met these criteria for the treatment of chronic and debilitating conditions.
For stakeholders, particularly patients and healthcare providers, this news could represent increased accessibility to a potentially life-changing therapy. It is essential for the medical community to observe the outcomes as larger populations gain access to IB-Stim, which could further validate its clinical utility and support broader adoption.
Moreover, the anticipation of all data being published may signal forthcoming peer-reviewed studies that could bolster the therapy's credibility. Such publications are crucial for ongoing medical research and for informing future clinical guidelines.
The expansion of policy coverage for NeurAxis's neuromodulation therapies by BCBSKC could have implications for healthcare economics, particularly in the Kansas City region. By increasing the insured population with access to these therapies, there may be a shift in the treatment paradigm for chronic conditions.
One must consider the potential economic benefits of improved disease management through neuromodulation therapies, such as reduced hospital admissions and lower long-term healthcare costs. However, the initial cost of adopting new medical technologies can be high and it will be crucial to analyze the cost-benefit ratio from a broader healthcare system perspective.
Additionally, the company's strategy to drive market adoption post-coverage could influence competitive dynamics in the neuromodulation space, potentially affecting pricing and healthcare spending. Stakeholders, including payers and providers, will need to balance the cost implications with the clinical outcomes to ensure economic sustainability.
CARMEL, Ind., March 04, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced receipt of Blue Cross and Blue Shield of Kansas City (“BCBSKC”) policy coverage for approximately one million lives. BCBSKC provides coverage in the Kansas City, Missouri metropolitan areas including Johnson and Wyandotte counties in Kansas.
“We are happy to announce new policy coverage from BCBSKC, expanding our total covered lives to now approximately 9.25 million individuals,” said Brian Carrico, President and Chief Executive Officer of NeurAxis. “We remain focused on executing on our commercial strategy, leveraging clinical evidence supporting IB-Stim to obtain payer coverage and then driving market adoption of our technology. As we close in on all data being published, we look forward to receiving positive responses from payers on a national level.”
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company’s stock, public health issues or other events, the Company’s compliance with applicable laws, the results of the Company’s clinical trials and perceptions thereof, the results of submissions to the FDA, the results of the shareholder vote to enable the issuance of the Preferred Stock, and factors described in the Risk Factors section of NeurAxis’s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contacts:
Company
NeurAxis, Inc.
info@neuraxis.com
Investor Relations
Gilmartin Group
IR@neuraxis.com
FAQ
What is the ticker symbol for NeurAxis?
What was announced by NeurAxis regarding Blue Cross and Blue Shield of Kansas City?
How many lives are now covered by NeurAxis after the announcement?
What is NeurAxis focused on in terms of their commercial strategy?
Who is the President and Chief Executive Officer of NeurAxis?
